Stock activists fire back at Allergan’s defensive moves, push for a company sale
Allergan’s attempt to assuage its critics — or at least shore up support among investors — by adding industry headliner Bob Hugin to the board and calling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
